Kidney transplant recipients deal with taking anti-rejection meds for life. Talaris is developing an alternative to immunosuppression. Nancy Krieger, MD, Talaris Therapeutics Chief Medical Officer, explains how this new treatment will work and how it differs from what is currently prescribed. She also talks about how you can learn more about the clinical trials that are available.